Receptor, erbB-2
This graph shows the total number of publications written about "Receptor, erbB-2" by people in the URMC Research Network by year, and whether "Receptor, erbB-2" was a major or minor topic of these publication.
Below are the most recent publications written about "Receptor, erbB-2" by people in Profiles.
-
Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011; 18(4):451-64.
-
Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Janarthanan B, Cheney RT. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod Pathol. 2011 Aug; 24(8):1055-9.
-
Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol. 2011 Jul; 24(7):899-907.
-
Tang P, Wei B, Yang WJ, Liu YS, Bu H. [Prognostic factors of breast cancer]. Zhonghua Bing Li Xue Za Zhi. 2011 Feb; 40(2):73-6.
-
Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010 Nov; 28(9):978-82.
-
Hicks DG, Janarthanan BR, Vardarajan R, Kulkarni SA, Khoury T, Dim D, Budd GT, Yoder BJ, Tubbs R, Schreeder MT, Estopinal NC, Beck RA, Wang Y, Ring BZ, Seitz RS, Ross DT. The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer. 2010; 10:108.
-
Barron JJ, Cziraky MJ, Weisman T, Hicks DG. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009 Aug; 14(8):760-8.
-
Plebani M, Lippi G. HER2: Closing the gap between laboratory testing and clinical practice. Am J Clin Pathol. 2009 Jun; 131(6):897-8; author reply 898-900.
-
Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT. TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res. 2009; 11(2):R17.
-
Tang P, Wei B, Hicks DG, Skinner K, Bu H. [Molecular phenotypes of breast cancer and their clinical application]. Zhonghua Bing Li Xue Za Zhi. 2009 Jan; 38(1):13-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
